Eton Pharmaceuticals Inc. (ETON)
Eton Pharmaceuticals Statistics
Share Statistics
Eton Pharmaceuticals has 26.82M shares outstanding. The number of shares has increased by 4.39% in one year.
| Shares Outstanding | 26.82M |
| Shares Change (YoY) | 4.39% |
| Shares Change (QoQ) | 0.69% |
| Owned by Institutions (%) | 50.72% |
| Shares Floating | 25.33M |
| Failed to Deliver (FTD) Shares | 129 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 402.63K, so 1.5% of the outstanding shares have been sold short.
| Short Interest | 402.63K |
| Short % of Shares Out | 1.5% |
| Short % of Float | 1.58% |
| Short Ratio (days to cover) | 1.53 |
Valuation Ratios
The PE ratio is -90.22 and the forward PE ratio is 13.8. Eton Pharmaceuticals's PEG ratio is -0.29.
| PE Ratio | -90.22 |
| Forward PE | 13.8 |
| PS Ratio | 8.84 |
| Forward PS | 2 |
| PB Ratio | 14.12 |
| P/FCF Ratio | 365.77 |
| PEG Ratio | -0.29 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Eton Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 1.22.
| Current Ratio | 2.06 |
| Quick Ratio | 1.29 |
| Debt / Equity | 1.22 |
| Debt / EBITDA | -20.62 |
| Debt / FCF | 31.73 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.26M |
| Profits Per Employee | $-123.32K |
| Employee Count | 31 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.02 |
Taxes
| Income Tax | 15K |
| Effective Tax Rate | -0.39% |
Stock Price Statistics
The stock price has increased by 352% in the last 52 weeks. The beta is 1.34, so Eton Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.34 |
| 52-Week Price Change | 352% |
| 50-Day Moving Average | 14.31 |
| 200-Day Moving Average | 10.51 |
| Relative Strength Index (RSI) | 71.02 |
| Average Volume (20 Days) | 253.85K |
Income Statement
In the last 12 months, Eton Pharmaceuticals had revenue of 39.01M and earned -3.82M in profits. Earnings per share was -0.15.
| Revenue | 39.01M |
| Gross Profit | 23.41M |
| Operating Income | -2.6M |
| Net Income | -3.82M |
| EBITDA | -1.45M |
| EBIT | -2.6M |
| Earnings Per Share (EPS) | -0.15 |
Balance Sheet
The company has 14.94M in cash and 29.92M in debt, giving a net cash position of -14.98M.
| Cash & Cash Equivalents | 14.94M |
| Total Debt | 29.92M |
| Net Cash | -14.98M |
| Retained Earnings | -107.89M |
| Total Assets | 76.12M |
| Working Capital | 21.07M |
Cash Flow
In the last 12 months, operating cash flow was 969K and capital expenditures -26K, giving a free cash flow of 943K.
| Operating Cash Flow | 969K |
| Capital Expenditures | -26K |
| Free Cash Flow | 943K |
| FCF Per Share | 0.04 |
Margins
Gross margin is 60.01%, with operating and profit margins of -6.66% and -9.8%.
| Gross Margin | 60.01% |
| Operating Margin | -6.66% |
| Pretax Margin | -9.76% |
| Profit Margin | -9.8% |
| EBITDA Margin | -3.72% |
| EBIT Margin | -6.66% |
| FCF Margin | 2.42% |
Dividends & Yields
ETON does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ETON is $26, which is 53.4% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $26 |
| Price Target Difference | 53.4% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 3.72 |
| Piotroski F-Score | 4 |